Hundreds of cancer sufferers in the UK shall be given a cannabis-based drug to treat their aggressive brain tumours as half of a world first trial, it was introduced right now.

The Brain Tumour Charity raised £400,000 to again the three-year research, which can complement glioblastoma sufferers’ chemotherapy therapy with Sativex — an oral spray containing cannabinoids.

Experts at the University of Leeds will have a look at whether or not the addition of the drug extends life for folks recognized with the cancer. 

The trial will start recruiting 230 sufferers at 15 hospitals throughout the UK early subsequent yr. 

If the drug works, it might turn into the first addition to NHS therapy for glioblastoma in additional than a decade.  

Professor Susan Short, chief trial investigator and an professional in medical oncology and neuro-oncology at Leeds University, mentioned cannabinoids have ‘well-described effects’ in the brain and the trial will decide whether or not they assist treat the most typical and aggressive kind of brain cancer. 

Around 2,200 individuals are recognized with glioblastoma yearly in England. Even after intensive therapy, nearly all glioblastomas recur and the common survival is simply 12 to 18 months after analysis.

The trial — dubbed ARISTOCRAT — will decide whether or not including Sativex to chemotherapy extends the sufferers’ lives, slows the development of their illness or improves their high quality of life. Sativex is sprayed into the mouth and accommodates cannabinoids THC and CBD. Pictured: medicinal…

Original Author Link click here to read complete story..

Hundreds of cancer sufferers in the UK shall be given a cannabis-based drug to treat their aggressive brain tumours as half of a world first trial, it was introduced right now.

The Brain Tumour Charity raised £400,000 to again the three-year research, which can complement glioblastoma sufferers’ chemotherapy therapy with Sativex — an oral spray containing cannabinoids.

Experts at the University of Leeds will have a look at whether or not the addition of the drug extends life for folks recognized with the cancer. 

The trial will start recruiting 230 sufferers at 15 hospitals throughout the UK early subsequent yr. 

If the drug works, it might turn into the first addition to NHS therapy for glioblastoma in additional than a decade.  

Professor Susan Short, chief trial investigator and an professional in medical oncology and neuro-oncology at Leeds University, mentioned cannabinoids have ‘well-described effects’ in the brain and the trial will decide whether or not they assist treat the most typical and aggressive kind of brain cancer. 

Around 2,200 individuals are recognized with glioblastoma yearly in England. Even after intensive therapy, nearly all glioblastomas recur and the common survival is simply 12 to 18 months after analysis.

The trial ¿ dubbed ARISTOCRAT ¿ will determine whether adding Sativex to chemotherapy extends the patients' lives, slows the progression of their disease or improves their quality of life. Sativex is sprayed into the mouth and contains cannabinoids THC and CBD. Pictured: medicinal cannabis

The trial — dubbed ARISTOCRAT — will decide whether or not including Sativex to chemotherapy extends the sufferers’ lives, slows the development of their illness or improves their high quality of life. Sativex is sprayed into the mouth and accommodates cannabinoids THC and CBD. Pictured: medicinal…

Source link

Source link